Glutamyl cysteine ethyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glutamyl cysteine ethyl ester
• 英文别名: (4S)-4-amino-5-[[(2R)-1-ethoxy-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
• 化学式: C₁₀H₁₈N₂O₅S
• 分子量: 278.33
• InChiKey: ACGMFEAFBBMUMQ-BQBZGAKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DES TROUBLES SENSIBLES À LA CYSTÉAMINE
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2019060634A1

  公开（公告）日：2019-03-28

  The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

  这项发明涉及治疗囊性氨基酸病和其他对半胱氨酸敏感的疾病的方法，包括在体内给予可转化为半胱氨酸的二硫化物。该方法可以包括向受试者单独给予还原剂，以增加半胱氨酸在给予二硫化物后产生的生物利用度，并延长血浆药代动力学特性。该方法允许受试者体内维持持续的半胱氨酸血浆浓度。
• Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
  申请人：Thiogenesis Therapeutics, Inc.

  公开号：US11173135B2

  公开（公告）日：2021-11-16

  The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.

  本发明的特点是组合物、方法和试剂盒含有(i)一种或多种可在体内转化为半胱胺的半胱胺前体化合物，以及(ii)可选的增强这种转化的制剂，配制成一系列半胱胺的药代动力学特征，可根据不同的患者和疾病量身定制。本发明的另一个特点是，在治疗胱氨酸沉着症和其他半胱胺敏感性疾病时，治疗物质的给药方式各不相同。特别是将活性成分与药用辅料相结合的制剂，可使半胱胺的血浆浓度保持稳定。
• Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
  申请人：——

  公开号：US20040229815A1

  公开（公告）日：2004-11-18

  The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug.

  本发明涉及通过使细胞与巯基保护的谷胱甘肽原药或巯基保护的半胱氨酸原药接触来降低细胞中的氧化应激、增加细胞中的谷胱甘肽水平、增加细胞中的L-半胱氨酸水平以及降低肝细胞毒性的组合物和方法。
• Albumin fusion proteins
  申请人：Rosen A. Craig

  公开号：US20060194735A1

  公开（公告）日：2006-08-31

  The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

  本发明包括白蛋白融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。
• NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
  申请人：HUMAN GENOME SCIENCES, INC.

  公开号：EP1259642A1

  公开（公告）日：2002-11-27